MediciNova Reports Positive Phase 2 Results for MN-001 Liver Treatment

Key Facts

1MediciNova announced positive topline results from its Phase 2 clinical trial of MN-001, showing significant improvements in HDL-C and triglyceride levels.

MediciNova announced positive topline results from its Phase 2 clinical trial of MN-001, showing significant improvements in HDL-C and triglyceride levels. GlobeNewswire reported that the trial evaluated the efficacy of MN-001 (Tipelukast) in patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, achieving statistically significant reductions in triglycerides and body weight.

MNOV closed at $2.58 on September 25, 2026, prior to the release of the clinical data regarding treatments for NAFLD associated with type 2 diabetes. The stock traded between a low of $2.53 and a high of $2.69 during the September 25, 2026 session as the company progresses through its biotechnological development milestones.